Show Notes
In this special WCLC 2026 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss daily highlights from the conference and ask what changes in clinic on Monday.
A ROS1 drug that protects the brain and a first line combination that could not beat a decade old standard. Dr. Alexander Drilon brings the first line ARROS-1 data on zidesamtinib, and Dr. Giannis Mountzios walks us through EVOKE-03, sacituzumab govitecan plus pembrolizumab in PD-L1 high lung cancer.
Guests:
Alexander Drilon, MD Chief, Early Drug Development Service Memorial Sloan Kettering Cancer Center Professor, Weill Cornell Medical College Attending Physician, Thoracic Oncology Service
Giannis Mountzios, MD, MSc, PhD Medical Oncologist and Director at the 4th Oncology Department and Clinical Trials Unit Henry Dunant Hospital Center Athens, Greece,
More from Lung Cancer Considered
The 2026 World Conference on Lung Cancer brought together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2026 in world languages.
The 2026 World Conference on Lung Cancer brought together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2026 in world languages.
The 2026 World Conference on Lung Cancer brought together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2026 in world languages.
Recorded at the 2026 IASLC World Conference on Lung Cancer in Seoul, this special Early Career Takeover episode explores what this annual meeting offers to researchers and clinicians at the start of their careers.
The WHO Eastern Mediterranean Region (EMRO) faces unique challenges around exposures, non-conventional smoking, lung cancer screening, molecular profiling, and evolving therapies in lung cancer. To address this, the inaugural joint IASLC/EMRO workshop took place at the 2026 World Conference on Lung Cancer (WCLC) in Seoul.